M&A / Jazz’s $7.2 Billion GW Pharma Deal: A Major Boost for Cannabinoid Research
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical…
Address: 6 Henrietta Street
London
WC2E 8PU
Tel: +44 (0)20 7557 7500
Web: http://www.mvmlifescience.com/
Heptares is a drug discovery company creating new medicines targeting G-protein-coupled receptors (GPCRs).
The Company is currently leveraging its GPCR expertise and proprietary StaR® technology to build a pipeline of best-in-class and first-in-class GPCR-targeted medicines for the treatment of CNS, metabolic and other diseases.
Heptares Therapeutics Ltd has already four-year collaboration with AstraZeneca (2011), where they focused on developing small molecule and antibody candidates targeting specific GPCRs linked to CNS/pain, CV/metabolic and inflammatory disorders.
Also, an approximately $100 million drug discovery collaboration with Takeda (2011) focused on a GPCR linked to CNS disorders.
Moreover, $200 million alliance with the Novartis Option Fund (2009) focused on single GPCR target of strategic interest to Novartis. Novartis and Heptares jointly announced the successful first-ever stabilisation of this previously intractable GPCR using the Heptares technology.
Heptares Therapeutics Ltd deploys structure-based drug discovery techniques to identify potent and selective drug candidates to previously undruggable targets. They develop small molecule and antibody candidates targeting specific GPCRs linked to CNS/pain, CV/metabolic and inflammatory disorders.
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical…
When the European Medicines Agency (EMA) relocated from London to Amsterdam after the UK announced its decision to…
The signing of an agreement on the terms of a future trade relationship between Japan and the UK has been welcomed…
US Merck (MSD globally) is following through on a 2017 commitment to invest in a new early research hub in central…
Jameel Zayed of Leyton, the UK’s leading innovation funding consultancy, highlights the British pharmaceutical…
Below we highlight some recent developments in pharma and healthcare in the UK, including drug shortages in British…
The world’s two leading vaccine producers, GSK of the UK and France’s Sanofi, last week announced that they are…
With Brexit now confirmed, the UK government has been playing up the country’s scientific credentials. The aim is…
Friday January 31 2020 was officially dubbed “Brexit Day” as the UK finally left the EU, following British…
Although biotech financing in the UK took a hit last year in large part thanks to uncertainty around Brexit, 2019…
GW Pharmaceuticals reports that sales of its CBD drug Epidiolex more than doubled in the second quarter of 2019,…
Formed in 2015, listed UK start-up Amryt targets rare diseases with high unmet medical need. With one commercial…